Tom Wilemon

From left, Ken Lau, PhD, Bob Chen, Qi Liu, PhD, Joseph Rolland, PhD, Martha Shrubsole, PhD, Robert Coffey, MD, and colleagues are studying how polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine. (photo by Erin O. Smith)
December 14, 2021

Study sets framework for precision surveillance of colorectal cancer

Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.

By Tom Wilemon
November 18, 2021

Team receives Association of Community Cancer Centers Innovator Award

A team of Vanderbilt employees have received and award for implementing a streamlined follow-up protocol for patients who may not know they have cancer.

By Tom Wilemon
November 18, 2021

Chic Awearness gala to support ovarian cancer research set for Dec. 6

Chic Awearness, a fashion show and fundraiser for ovarian cancer research, returns as an in-person event from 6:30 p.m. to 8:30 p.m. on Monday, Dec. 6.

By Tom Wilemon
November 4, 2021

Koerkenmeier named VICC associate nursing officer

By Tom Wilemon
October 28, 2021

VICC’s Mayer departing to take new role with AstraZeneca

Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

By Tom Wilemon
October 21, 2021

Study to evaluate how environment impacts cancer risk

Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.

By Tom Wilemon
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.
By Tom Wilemon
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
By Tom Wilemon
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
By Tom Wilemon
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
By Tom Wilemon
August 19, 2021

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
By Tom Wilemon
August 12, 2021

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
By Tom Wilemon
1 … 14 15 16 17 18 … 39